Mf59^®-Adjuvanted Seasonalinfluenza Vaccine

• Molinari NA , Ortega-SanchezIR, MessonnierMLet al.: The annual impact of seasonal influenza in the US: measuring disease burden and costs.Vaccine25(27), 5086–5096(2007).
   PubMed Web of Science ®Google Scholar
• Whitley RJ , MontoAS: Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents.J. Infect. Dis.194(Suppl. 2), S133–S138 (2006).
   PubMed Web of Science ®Google Scholar
• Barker WH , BorisuteH, CoxC: A study of the impact of influenza on the functional status of frail older people.Arch. Intern. Med.158(6), 645–650(1998).
   PubMedGoogle Scholar
• McElhaney JE : The unmet need in the elderly: designing new influenza vaccines for older adults.Vaccine23(Suppl. 1), S10–S25 (2005).
   PubMed Web of Science ®Google Scholar
• Fiore AE , ShayDK, BroderKet al.: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008.MMWR Recomm. Rep.57(RR-7), 1–60(2008).
   PubMedGoogle Scholar
• Vu T , FarishS, JenkinsM, KellyH: A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community.Vaccine20(13), 1831–1836(2002).
   PubMed Web of Science ®Google Scholar
• Puig-Barbera J , MarquezCS: Effectiveness of influenza vaccine in the elderly. A critical review of the bibliography.Med. Clin. (Barc.)105(17), 645–648(1995).
   PubMed Web of Science ®Google Scholar
• Jefferson T : Influenza vaccination: policy versus evidence.BMJ333(7574), 912–915(2006).
   PubMedGoogle Scholar
• Glezen WP , SimonsenL: Commentary: Benefits of influenza vaccine in US elderly – new studies raise questions.Int. J. Epidemiol.35(2), 352–353(2006).
   PubMed Web of Science ®Google Scholar
• Hannoun C , MegasF, PiercyJ: Immunogenicity and protective efficacy of influenza vaccination.Virus Res.103(1–2), 133–138(2004).
   PubMed Web of Science ®Google Scholar
• Carrat F , FlahaultA: Influenza vaccine: the challenge of antigenic drift.Vaccine25(39–40), 6852–6862(2007).
   PubMed Web of Science ®Google Scholar
• Lin YP , GregoryV, BennettM, HayA: Recent changes among human influenza viruses.Virus Res.103(1–2), 47–52(2004).
   PubMed Web of Science ®Google Scholar
• Shaw MW , XuX, LiYet al.: Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000–2001 and 2001–2002 seasons.Virology303(1), 1–8(2002).
   PubMed Web of Science ®Google Scholar
• Legrand J , VerguE, FlahaultA: Real-time monitoring of the influenza vaccine field effectiveness.Vaccine24(44–46), 6605–6611(2006).
   PubMed Web of Science ®Google Scholar
• Simonsen L , ClarkeMJ, WilliamsonGDet al.: The impact of influenza epidemics on mortality: introducing a severity index.Am. J. Public Health87(12), 1944–1950(1997).
   PubMed Web of Science ®Google Scholar
• Treanor J : Influenza vaccine – outmaneuvering antigenic shift and drift.N. Engl. J. Med.350(3), 218–220(2004).
   PubMed Web of Science ®Google Scholar
• Kumar R , BurnsEA: Age-related decline in immunity: implications for vaccine responsiveness.Expert Rev. Vaccines7(4), 467–479(2008).
   PubMed Web of Science ®Google Scholar
• O‘Hagan DT : MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.Expert Rev. Vaccines6(5), 699–710(2007).
   PubMed Web of Science ®Google Scholar
• Moser C , MetcalfeIC, ViretJF: Virosomal adjuvanted antigen delivery systems.Expert. Rev. Vaccines2(2), 189–196(2003).
   PubMedGoogle Scholar
• Belshe RB , NewmanFK, WilkinsKet al.: Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults.Vaccine25(37–38), 6755–6763(2007).
   PubMed Web of Science ®Google Scholar
• Holland D , BooyR, De Looze F et al.: Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis.198(5), 650–658(2008).
   PubMed Web of Science ®Google Scholar
• Gluck R , MischlerR, DurrerPet al.: Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant.J. Infect. Dis.181(3), 1129–1132(2000).
   PubMed Web of Science ®Google Scholar
• Gerhard W , MozdzanowskaK, ZharikovaD: Prospects for universal influenza virus vaccine.Emerg. Infect. Dis.12(4), 569–574(2006).
   PubMed Web of Science ®Google Scholar
• Fiers W , De Filette M, Birkett A, Neirynck S, Min JW: A ‘universal’ human influenza A vaccine. Virus Res.103(1–2), 173–176(2004).
   PubMed Web of Science ®Google Scholar
• Nicolas JF , GuyB: Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice.Expert Rev. Vaccines7(8), 1201–1214(2008).
   PubMed Web of Science ®Google Scholar
• Mutsch M , ZhouW, RhodesPet al.: Use of the inactivated intranasal influenza vaccine and the risk of Bell‘s palsy in Switzerland.N. Engl. J. Med.350(9), 896–903(2004).
   PubMed Web of Science ®Google Scholar
• Laurent PE , BonnetS, AlchasPet al.: Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system.Vaccine25(52), 8833–8842(2007).
   PubMed Web of Science ®Google Scholar
• Belshe RB , NewmanFK, CannonJet al.: Serum antibody responses after intradermal vaccination against influenza.N. Engl. J. Med.351(22), 2286–2294(2004).
   PubMed Web of Science ®Google Scholar
• Van Damme P , Oosterhuis-KafejaF, Van der Wielen M et al.: Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine27(3), 454–459(2009).
   PubMed Web of Science ®Google Scholar
• Schijns VE : Induction and direction of immune responses by vaccine adjuvants.Crit. Rev. Immunol.21(1–3), 75–85(2001).
   PubMed Web of Science ®Google Scholar
• de Bruijn IA , NautaJ, CramerWC, GerezL, PalacheAM: Clinical experience with inactivated, virosomal influenza vaccine.Vaccine23(Suppl. 1), S39–S49 (2005).
   PubMed Web of Science ®Google Scholar
• Schultze V , D‘AgostoV, WackA, NovickiD, ZornJ, HennigR: Safety of MF59 adjuvant.Vaccine26(26), 3209–3222(2008).
   PubMed Web of Science ®Google Scholar
• Baldo V , MenegonT, BonelloC, FloreaniA, TrivelloR: Comparison of three different influenza vaccines in institutionalised elderly.Vaccine19(25–26), 3472–3475(2001).
   PubMed Web of Science ®Google Scholar
• Ruf BR , ColbergK, FrickM, PreuscheA: Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.Infection32(4), 191–198(2004).
   PubMed Web of Science ®Google Scholar
• Pregliasco F , MensiC, SerpilliWet al.: Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly.Aging (Milano)13(1), 38–43(2001).
   PubMedGoogle Scholar
• de Bruijn I , MeyerI, GerezL, NautaJ, GiezemanK, PalacheB: Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.Vaccine26(1), 119–127(2007).
   PubMed Web of Science ®Google Scholar
• Puig-Barbera J , Gonzalez-VidalD: MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.Expert Rev. Vaccines6(5), 659–665(2007).
   PubMed Web of Science ®Google Scholar
• Del Giudice G , HilbertAK, BugariniRet al.: An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.Vaccine24(16), 3063–3065(2006).
   PubMed Web of Science ®Google Scholar
• Ansaldi F , BacilieriS, DurandoPet al.: Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.Vaccine26(12), 1525–1529(2008).
   PubMed Web of Science ®Google Scholar
• Puig-Barbera J , Diez-DomingoJ, PerezHS, BelenguerVA, GonzalezVD: Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age.Vaccine23(3), 283–289(2004).
   PubMed Web of Science ®Google Scholar
• Puig-Barbera J , Diez-DomingoJet al.: Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly.Vaccine25(42), 7313–7321(2007).
   PubMed Web of Science ®Google Scholar
• Radosevic K , RodriguezA, MintardjoRet al.: Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.Vaccine26(29–30), 3640–3646(2008).
   PubMed Web of Science ®Google Scholar
• Del Giudice G , FragapaneE, BugariniRet al.: Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene.Clin. Vaccine Immunol.13(9), 1010–1013(2006).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I , BorkowskiA, VanwolleghemTet al.: Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.Lancet370(9587), 580–589(2007).
   PubMed Web of Science ®Google Scholar
• Levie K , Leroux-RoelsI, HoppenbrouwersKet al.: An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.J. Infect. Dis.198(5), 642–649(2008).
   PubMed Web of Science ®Google Scholar
• Mosca F , TrittoE, MuzziAet al.: Molecular and cellular signatures of human vaccine adjuvants.Proc. Natl Acad. Sci. USA105(30), 10501–10506(2008).
   PubMed Web of Science ®Google Scholar
• De Donato S , GranoffD, MinutelloMet al.: Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly.Vaccine17(23–24), 3094–3101(1999).
   PubMed Web of Science ®Google Scholar
• Podda A : The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine.Vaccine19(17–19), 2673–2680(2001).
   PubMed Web of Science ®Google Scholar
• Squarcione S , SgriciaS, BiasioLR, PerinettiE: Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.Vaccine21(11–12), 1268–1274(2003).
   PubMed Web of Science ®Google Scholar
• Banzhoff A , NacciP, PoddaA: A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis.Gerontology49(3), 177–184(2003).
   PubMed Web of Science ®Google Scholar
• Baldo V , BaldovinT, FloreaniA, MinuzzoM, TrivelloR: Response to influenza vaccine in people with non-protective HI antibody titers.Eur. J. Epidemiol.21(11), 843–845(2006).
   PubMed Web of Science ®Google Scholar
• Lawrence G , BoydI, McIntyreP, IsaacsD: Surveillance of adverse events following immunisation: Australia 2002 to 2003.Commun. Dis. Intell.28(3), 324–338(2004).
   Google Scholar

Website

• Committee for medicinal products for human use summary of positive opinion for IDflu. European Medicines Agency, 18th December 2008. (Accessed 27th January 2009) www.emea.europa.eu/pdfs/human/opinion/Idflu_64294908en.pdf>
   Google Scholar